Epoxides metabolically produced from some known carcinogens and from some clinically used drugs. I. Differences in mutagenicity

H. R. Glatt, F. Oesch, A. Frigerio, S. Garattini

Research output: Contribution to journalArticle

Abstract

The epoxide metabolites of two clinically used drugs and an experimental psychotropic agent, carbamazepine 10,11 oxide, cyproheptadine 10,11 oxide and cyclobenzaprine 10,11 oxide, were fully devoid of any mutagenic activity under conditions where K region epoxide metabolites of some known carcinogens, such as benzo(a)purene, proved to be potent frameshift mutational agents for Salmonella typhimurium TA 1537 and TA 1538. All epoxides tested were non mutagenic for TA 1535, designed to detect substitution mutations. The 10,11 epoxides of the three drugs, carbamazepine, cyproheptadine and cyclobenzaprine, were not cytotoxic to any of the bacterial tester strains used, precluding that mutagenicity might have been overshadowed by cytotoxicity. When the mutagen precursor, benzo(a)pyrene, was incubated together with TA 1537 and a mammalian microsomal preparation in the presence of a system generating the cofactor necessary for monooxygenase activity, activation to mutagenic species was observed which was dramatically increased in the presence of a potent epoxide hydratase inhibitor, 1,1,1 trichloropropene 2,3 oxide, suggesting epoxide(s) as the (or one of the) mutagenically active species metabolically produced in situ. None of these effects was observed with the three medical drugs. Moreover, the observation that the alkene oxide 4 phenylstyrene 7,8 oxide is mutagenic to the two strains TA 1537 and TA 1538 but the K region arene oxide derived from 7,12 dimethylbenz(a)anthracene is inactive for the latter strain indicates that epoxidation of an aromatic double bond of a polycyclic hydrocarbon is neither a necessary nor a satisfying condition for frameshift mutagenesis to occur.

Original languageEnglish
Pages (from-to)787-797
Number of pages11
JournalInternational Journal of Cancer
Volume16
Issue number5
Publication statusPublished - 1975

Fingerprint

Epoxy Compounds
Carcinogens
Oxides
Cyproheptadine
Pharmaceutical Preparations
Trichloroepoxypropane
Cyclic Hydrocarbons
Epoxide Hydrolases
Benzo(a)pyrene
Psychotropic Drugs
Carbamazepine
Mutagens
Alkenes
Salmonella typhimurium
Mixed Function Oxygenases
Mutagenesis
Mutation
cyclobenzaprine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Epoxides metabolically produced from some known carcinogens and from some clinically used drugs. I. Differences in mutagenicity. / Glatt, H. R.; Oesch, F.; Frigerio, A.; Garattini, S.

In: International Journal of Cancer, Vol. 16, No. 5, 1975, p. 787-797.

Research output: Contribution to journalArticle

@article{9bf2e32400e94d0aa03754eb9bdeab87,
title = "Epoxides metabolically produced from some known carcinogens and from some clinically used drugs. I. Differences in mutagenicity",
abstract = "The epoxide metabolites of two clinically used drugs and an experimental psychotropic agent, carbamazepine 10,11 oxide, cyproheptadine 10,11 oxide and cyclobenzaprine 10,11 oxide, were fully devoid of any mutagenic activity under conditions where K region epoxide metabolites of some known carcinogens, such as benzo(a)purene, proved to be potent frameshift mutational agents for Salmonella typhimurium TA 1537 and TA 1538. All epoxides tested were non mutagenic for TA 1535, designed to detect substitution mutations. The 10,11 epoxides of the three drugs, carbamazepine, cyproheptadine and cyclobenzaprine, were not cytotoxic to any of the bacterial tester strains used, precluding that mutagenicity might have been overshadowed by cytotoxicity. When the mutagen precursor, benzo(a)pyrene, was incubated together with TA 1537 and a mammalian microsomal preparation in the presence of a system generating the cofactor necessary for monooxygenase activity, activation to mutagenic species was observed which was dramatically increased in the presence of a potent epoxide hydratase inhibitor, 1,1,1 trichloropropene 2,3 oxide, suggesting epoxide(s) as the (or one of the) mutagenically active species metabolically produced in situ. None of these effects was observed with the three medical drugs. Moreover, the observation that the alkene oxide 4 phenylstyrene 7,8 oxide is mutagenic to the two strains TA 1537 and TA 1538 but the K region arene oxide derived from 7,12 dimethylbenz(a)anthracene is inactive for the latter strain indicates that epoxidation of an aromatic double bond of a polycyclic hydrocarbon is neither a necessary nor a satisfying condition for frameshift mutagenesis to occur.",
author = "Glatt, {H. R.} and F. Oesch and A. Frigerio and S. Garattini",
year = "1975",
language = "English",
volume = "16",
pages = "787--797",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Epoxides metabolically produced from some known carcinogens and from some clinically used drugs. I. Differences in mutagenicity

AU - Glatt, H. R.

AU - Oesch, F.

AU - Frigerio, A.

AU - Garattini, S.

PY - 1975

Y1 - 1975

N2 - The epoxide metabolites of two clinically used drugs and an experimental psychotropic agent, carbamazepine 10,11 oxide, cyproheptadine 10,11 oxide and cyclobenzaprine 10,11 oxide, were fully devoid of any mutagenic activity under conditions where K region epoxide metabolites of some known carcinogens, such as benzo(a)purene, proved to be potent frameshift mutational agents for Salmonella typhimurium TA 1537 and TA 1538. All epoxides tested were non mutagenic for TA 1535, designed to detect substitution mutations. The 10,11 epoxides of the three drugs, carbamazepine, cyproheptadine and cyclobenzaprine, were not cytotoxic to any of the bacterial tester strains used, precluding that mutagenicity might have been overshadowed by cytotoxicity. When the mutagen precursor, benzo(a)pyrene, was incubated together with TA 1537 and a mammalian microsomal preparation in the presence of a system generating the cofactor necessary for monooxygenase activity, activation to mutagenic species was observed which was dramatically increased in the presence of a potent epoxide hydratase inhibitor, 1,1,1 trichloropropene 2,3 oxide, suggesting epoxide(s) as the (or one of the) mutagenically active species metabolically produced in situ. None of these effects was observed with the three medical drugs. Moreover, the observation that the alkene oxide 4 phenylstyrene 7,8 oxide is mutagenic to the two strains TA 1537 and TA 1538 but the K region arene oxide derived from 7,12 dimethylbenz(a)anthracene is inactive for the latter strain indicates that epoxidation of an aromatic double bond of a polycyclic hydrocarbon is neither a necessary nor a satisfying condition for frameshift mutagenesis to occur.

AB - The epoxide metabolites of two clinically used drugs and an experimental psychotropic agent, carbamazepine 10,11 oxide, cyproheptadine 10,11 oxide and cyclobenzaprine 10,11 oxide, were fully devoid of any mutagenic activity under conditions where K region epoxide metabolites of some known carcinogens, such as benzo(a)purene, proved to be potent frameshift mutational agents for Salmonella typhimurium TA 1537 and TA 1538. All epoxides tested were non mutagenic for TA 1535, designed to detect substitution mutations. The 10,11 epoxides of the three drugs, carbamazepine, cyproheptadine and cyclobenzaprine, were not cytotoxic to any of the bacterial tester strains used, precluding that mutagenicity might have been overshadowed by cytotoxicity. When the mutagen precursor, benzo(a)pyrene, was incubated together with TA 1537 and a mammalian microsomal preparation in the presence of a system generating the cofactor necessary for monooxygenase activity, activation to mutagenic species was observed which was dramatically increased in the presence of a potent epoxide hydratase inhibitor, 1,1,1 trichloropropene 2,3 oxide, suggesting epoxide(s) as the (or one of the) mutagenically active species metabolically produced in situ. None of these effects was observed with the three medical drugs. Moreover, the observation that the alkene oxide 4 phenylstyrene 7,8 oxide is mutagenic to the two strains TA 1537 and TA 1538 but the K region arene oxide derived from 7,12 dimethylbenz(a)anthracene is inactive for the latter strain indicates that epoxidation of an aromatic double bond of a polycyclic hydrocarbon is neither a necessary nor a satisfying condition for frameshift mutagenesis to occur.

UR - http://www.scopus.com/inward/record.url?scp=0016759957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016759957&partnerID=8YFLogxK

M3 - Article

C2 - 1102464

AN - SCOPUS:0016759957

VL - 16

SP - 787

EP - 797

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 5

ER -